Two roads for oncolytic immunotherapy development
Abstract Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) administration. While this may allow easy access to metastatic lesions, there is limit...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | http://link.springer.com/article/10.1186/s40425-019-0515-2 |